Tekla Capital Management LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 29.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 810,087 shares of the biopharmaceutical company’s stock after selling 336,602 shares during the quarter. Pfizer comprises about 1.0% of Tekla Capital Management LLC’s investment portfolio, making the stock its 25th biggest holding. Tekla Capital Management LLC’s holdings in Pfizer were worth $27,211,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently made changes to their positions in the business. Shine Investment Advisory Services Inc. bought a new stake in shares of Pfizer in the 2nd quarter worth $102,000. Mckinley Capital Management LLC Delaware bought a new stake in shares of Pfizer in the second quarter worth $103,000. D. Scott Neal Inc. grew its holdings in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 504 shares during the period. Herndon Capital Management LLC bought a new stake in shares of Pfizer in the second quarter worth $120,000. Finally, Franklin Parlapiano Turner & Welch LLC bought a new stake in shares of Pfizer in the first quarter worth $121,000. Institutional investors and hedge funds own 69.89% of the company’s stock.
Shares of Pfizer Inc. (PFE) traded up $0.26 during trading on Monday, hitting $36.00. The stock had a trading volume of 2,102,077 shares, compared to its average volume of 19,939,289. Pfizer Inc. has a fifty-two week low of $30.90 and a fifty-two week high of $36.78. The stock has a market capitalization of $213,035.67, a P/E ratio of 14.30, a price-to-earnings-growth ratio of 2.52 and a beta of 1.01. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. During the same period in the previous year, the business earned $0.61 earnings per share. The business’s revenue was up .9% on a year-over-year basis. analysts forecast that Pfizer Inc. will post 2.59 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Friday, November 10th were given a $0.32 dividend. The ex-dividend date was Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.56%. Pfizer’s payout ratio is 79.01%.
PFE has been the subject of several research analyst reports. Cowen set a $43.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Monday, August 14th. Jefferies Group set a $35.00 price objective on Pfizer and gave the stock a “neutral” rating in a report on Thursday, August 24th. Berenberg Bank reaffirmed a “hold” rating and issued a $36.00 price objective (down previously from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. Deutsche Bank set a $38.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. Finally, Goldman Sachs Group set a $36.00 price objective on Pfizer and gave the stock a “neutral” rating in a report on Wednesday, November 1st. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $38.77.
In related news, EVP Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $35.65, for a total value of $262,027.50. Following the sale, the executive vice president now directly owns 117,432 shares in the company, valued at $4,186,450.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Sally Susman sold 38,230 shares of the business’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the sale, the insider now owns 145,649 shares in the company, valued at $5,097,715. The disclosure for this sale can be found here. Insiders sold 60,280 shares of company stock worth $2,118,988 over the last 90 days. Company insiders own 0.06% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.